Supply chain guidance in the works
This article was originally published in The Gold Sheet
FDA plans to issue several supply-chain-related guidance documents in the coming year, the agency said in its annual guidance agenda, published Aug. 7 in the Federal Register. The commissioner's office is working on guidance for good importer practices. The Center for Drug Evaluation and Research has guidance in the works on active pharmaceutical ingredients, as well as on adding physical-chemical identifiers to solid oral dosage forms for anti-counterfeiting. The notice indicates other drug quality related guidance documents in preparation, including ones on annually reportable post-approval changes and parametric release (see story p. 1) as well as immunogenicity assessment; immunogenicity related assay development; standards recognition; penicillin definition, nonpenicillin beta-lactam contamination; process validation; genotoxic and carcinogenic impurities; and private labs
You may also be interested in...
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.